The purpose of the study is to develop enzymosomes as a novel site-specific medicine delivery technique. Enzymosomes take use of an enzyme__ampersandsignrsquo;s unique properties, which include the ability to bind to a specific substrate at a controlled rate and catalyse the product synthesis process. When an enzyme is covalently bonded to the surface of liposomes/lipid vesicles, enzymosomes are generated. Enzymes are connected via acylation, direct conjugation, physical adsorption, and encapsulation strategies to create enzymosomes with customized activity. Such innovative drug delivery systems exhibit effective drug release while decreasing the unfavorable side effects of previous treatment methods, leading in better long-term illness therapy. They might be a viable option to gout treatment, antiplatelet therapy, and other conventional therapies. Enzymosomes are supramolecular vesicular delivery methods that have recently been created and may enhance medication targeting, physicochemical properties, and hence bioavailability in pharmaceutics. It illustrates that drugs with a narrow precision have good benefits because targeting their site of action improves their overall pharmacodynamic and pharmacokinetic profile. It also improves half-life and achieves enzyme activity on particular places, such as malignant cells, by reducing alterations in normal enzymatic activity.